BioLargo, Inc.
BLGO
$0.2365
$0.00351.50%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -16.32% | 62.84% | 246.75% | 27.20% | 108.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.32% | 62.84% | 246.75% | 27.20% | 108.29% |
| Cost of Revenue | -16.43% | 112.53% | 358.85% | 30.12% | 101.41% |
| Gross Profit | -16.19% | 20.00% | 160.93% | 24.09% | 116.37% |
| SG&A Expenses | 14.05% | -8.12% | 34.23% | 29.21% | 20.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -133.33% |
| Total Operating Expenses | 5.86% | 29.85% | 92.94% | 30.91% | 49.98% |
| Operating Income | -164.48% | 29.08% | 44.86% | -59.96% | 50.04% |
| Income Before Tax | -69.80% | 29.71% | 52.03% | -56.88% | 27.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.80% | 29.71% | 52.03% | -56.88% | 27.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 146.74% | 69.81% | 13.76% | 47.77% | -8.78% |
| Net Income | -39.09% | 55.25% | 66.79% | -65.99% | 33.06% |
| EBIT | -164.48% | 29.08% | 44.86% | -59.96% | 50.04% |
| EBITDA | -161.79% | 29.79% | 46.22% | -59.78% | 50.08% |
| EPS Basic | -36.00% | 57.14% | 68.09% | -55.56% | 35.90% |
| Normalized Basic EPS | -300.00% | 77.27% | 72.00% | -100.00% | 81.25% |
| EPS Diluted | -36.00% | 57.14% | 68.09% | -55.56% | 35.90% |
| Normalized Diluted EPS | -300.00% | 77.27% | 72.00% | -100.00% | 81.25% |
| Average Basic Shares Outstanding | 3.81% | 4.36% | 4.03% | 4.84% | 5.21% |
| Average Diluted Shares Outstanding | 3.81% | 4.36% | 4.03% | 4.84% | 5.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |